NeuTec enrolls Aurograb Phase III

NeuTec (LSE:NTP) completed enrollment of 161 patients in a double-blind, placebo-controlled European Phase III trial of Aurograb plus vancomycin to treat methicillin-resistant S. aureus (MRSA) infecti...